Non-alcoholic fatty liver disease (NAFLD) has the potential to develop into hepatic steatosis and progress to terminal liver diseases such as cirrhosis and hepatocellular carcinoma. This human clinical study was aimed to demonstrate that SPB-201 (powdered-water extract of Artemisia annua) can improve liver function in subjects with non-alcoholic liver dysfunction at mild to moderate levels. A decrease of 271% in aspartate aminotransferase (AST) level and a significant decrease of 334% in alanine aminotransferase (ALT) level was observed in the test group as compared to the control group at the 4 weeks follow-up. In addition, after 8 weeks, decreases of 199% in AST level and 216% in ALT level were reported in the test group as compared to the control group. These results confirmed that SPB-201 intake significantly enhanced liver function and health. Moreover, the Multidimensional Fatigue Scale score of the test group decreased but that of the control group increased, implicating that SPB-201 also eliminated overall fatigue. No significant adverse events were observed among all subjects during the study. Taken together, our clinical study confirmed the excellent efficacy and safety of SPB-201 in liver function improvement, showing the possibility of SPB-201 as a functional food to restore liver dysfunction and treat liver diseases.

Citations

Citations to this article as recorded by  

• Herbal treatments for non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
  Dulmini Wathsala Rathnayake, Piumika Sooriyaarachchi, Madunil Anuk Niriella, Dileepa Ediriweera, Jennifer Perera
  Advances in Integrative Medicine.2025; 12(3): 100410.     CrossRef
• Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review
  Deepa Handu, Kim Stote, Tami Piemonte
  Nutrients.2025; 17(3): 453.     CrossRef
• Nature-Inspired Strategies in Cancer Management: The Potential of Plant Extracts in Modulating Tumour Biology
  Marcin Hołota, Małgorzata M. Posmyk
  International Journal of Molecular Sciences.2025; 26(14): 6894.     CrossRef
• Artemisinin Partial Resistance in Ugandan Children
  Pamela Weathers, Stephen M. Rich, Dominique Mazier
  JAMA.2025; 333(16): 1455.     CrossRef
• Gastroprotective Effects of Artemisia annua L., on an Hydrochloric Acid/Ethanol-Induced Acute Gastritis Model via Anti-Oxidative and Anti-Inflammatory Activities
  Sooyeon Choi, Soo-Yeon Ahn, Hee-Jin Yang, Su-Jin Park, Seong Hyun Ho, Byoungduck Han, Seon-Hee Kim
  Preventive Nutrition and Food Science.2025; 30(6): 570.     CrossRef
• Differential Anti-Fibrotic and Remodeling Responses of Human Dermal Fibroblasts to Artemisia sp., Artemisinin, and Its Derivatives
  Pamela Weathers, Melissa Towler, Bushra Hafeez Kiani, David Dolivo, Tanja Dominko
  Molecules.2024; 29(9): 2107.     CrossRef
• Artemisia argyi ethanol extract ameliorates nonalcoholic steatohepatitis-induced liver fibrosis by modulating gut microbiota and hepatic signaling
  Saruul Erdenebileg, Myungsuk Kim, Yunseong Nam, Kwang Hyun Cha, Tam Thi Le, Sang Hoon Jung, Chu Won Nho
  Journal of Ethnopharmacology.2024; 333: 118415.     CrossRef
• Traditional uses, Phytochemistry, Pharmacology, and Toxicology of the GenusArtemisia L. (Asteraceae): A High-value Medicinal Plant
  Manzoor Hussain, Rakesh Kr Thakur, Jabeena Khazir, Sajad Ahmed, Mohammad Imtiyaj Khan, Praveen Rahi, Latif Ahmad Peer, Pragadheesh Vppalayam Shanmugam, Satwinderjeet Kaur, Soom Nath Raina, Zafar Ahmad Reshi, Deepmala Sehgal, Vijay Rani Rajpal, Bilal Ahmad
  Current Topics in Medicinal Chemistry.2024; 24(4): 301.     CrossRef
• Mechanism Research of QingReJieDu Formula for Treating Hepatitis B Virus Based on Network Pharmacology
  Caixia Jia, Hongxing Wu, Aiqing Yang, Aiping Chen, Xueting Wang, Shuqin Ding, Baofeng Fan, Gangqiao Zhou, Zhihong Li, Jianxin Chen
  Phytomedicine.2024; 135: 155915.     CrossRef
• Protective impacts of Artemisia annua against hepatic toxicity induced by gentamicin
  Saed A Althobaiti, Safa H Qahl, Hind Toufig, Daklallah A Almalki, Omaima Nasir, Mohamed Mohamed Soliman
  Toxicology Research.2024;[Epub]     CrossRef
• Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis
  Lei-lei Wang, Pian-hong Zhang, Hui-hui Yan
  Frontiers in Nutrition.2023;[Epub]     CrossRef
• Artemisinin as a therapeuticvs.its more complexArtemisiasource material
  Pamela J. Weathers
  Natural Product Reports.2023; 40(7): 1158.     CrossRef
• Network Pharmacology‐Based Exploration on the Intervention of Qinghao Biejia Decoction on the Inflammation‐Carcinoma Transformation Process of Chronic Liver Disease via MAPK and PI3k/AKT Pathway
  Xin Cheng, Zhong-Xiao Han, Zi-Jie Su, Feng-Lin Zhang, Biao-Ping Li, Zhi-Rui Jiang, Ling Tang, Jia-Shun Yang, Usman Ali Ashfaq
  BioMed Research International.2022;[Epub]     CrossRef
• Artemisia extracts differ from artemisinin effects on human hepatic CYP450s 2B6 and 3A4 in vitro
  Ndeye F. Kane, Bushra H. Kiani, Matthew R. Desrosiers, Melissa J. Towler, Pamela J. Weathers
  Journal of Ethnopharmacology.2022; 298: 115587.     CrossRef
• A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease
  Na-yeon Kim, Mi-jung Yoon, Hong-sik Choi, Seung-mo Kim, Sang-chan Kim, Kyung-soon Kim
  The Journal of Internal Korean Medicine.2022; 43(4): 680.     CrossRef
• The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity
  Ke Fu, Cheng Wang, Cheng Ma, Honglin Zhou, Yunxia Li
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Toxicological safety evaluation of Qiguiyin formula in rats at the treatment phase and recovery phase
  Junying Ding, Xiang Gao, Fan Zhang, Yunxin Zhou, Siyang Li, Youran Lu, Qingquan Liu
  Journal of Ethnopharmacology.2021; 279: 114364.     CrossRef